Biotech

All Articles

Pfizer takes $230M hit after axing stopped working DMD genetics treatment

.Pfizer's period 3 Duchenne muscle dystrophy (DMD) genetics therapy failure has gone a $230 thousand...

AC Immune observes 'landmark' prospective in Alzheimer's medicine data

.After greater than 20 years of focus on neurodegenerative illness, Swiss biotech hvac Invulnerable ...

GSK loses ph. 2 HPV vaccination over lack of best-in-class potential

.GSK has ditched a phase 2 human papillomavirus (HPV) vaccine coming from its own pipe after determi...

OS Therapies refiles $6M IPO to finance HER2 medicine, preclinical ADCs

.OS Therapies will definitely list on the NYSE American supply exchange this morning using a $6.4 th...

ALX's fizzling CD47 feedback price sends supply spiraling down

.ALX Oncology's period 2 gastric cancer reaction price has weakened. After finding its own CD47 bloc...

Ionis axes eye illness coming from targets of Roche-partnered possibility after information disappoint

.Yet Another of Ionis Pharmaceuticals' vital midphase readouts has disappointed assumptions, causing...

Biogen's CEO pointed out no high-risk deals in 2023. He prepares to become daring

.While Biogen's pharma peers are actually searching for late-stage properties with little bit of thr...

Instil refills pipe in $2B biobucks deal with ImmunOnco

.Instil Biography has been a biotech seeking a pipe after it scrapped its own lead resources over th...

Biogen bows out Denali Alzheimer's collab

.Biogen has restored civil rights to an early Alzheimer's ailment system to Denali Therapeutics, lea...

Takeda taps new mind of US oncology organization-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of notable management hirings, firings as we...